NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Zafgen Inc (NASDAQ:ZFGN) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.27) by $0.03. View Zafgen's Earnings History.

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

5 Wall Street analysts have issued twelve-month price targets for Zafgen's shares. Their forecasts range from $0.78 to $17.00. On average, they expect Zafgen's share price to reach $7.70 in the next twelve months. This suggests a possible upside of 491.9% from the stock's current price. View Analyst Price Targets for Zafgen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Media headlines about ZFGN stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zafgen earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Zafgen.

Zafgen saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 823,200 shares, an increase of 58.1% from the January 15th total of 520,800 shares. Based on an average daily volume of 673,400 shares, the short-interest ratio is currently 1.2 days. Currently, 2.5% of the shares of the company are sold short. View Zafgen's Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Gilead Sciences (GILD), Micron Technology (MU) and AT&T (T).

Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.38%), Russell Investments Group Ltd. (1.06%), Point72 Asset Management L.P. (0.55%), Virtu Financial LLC (0.28%), Wedbush Securities Inc. (0.23%) and Jane Street Group LLC (0.16%). View Institutional Ownership Trends for Zafgen.

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wedbush Securities Inc. and State Street Corp. View Insider Buying and Selling for Zafgen.

ZFGN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., Virtu Financial LLC and Jane Street Group LLC. View Insider Buying and Selling for Zafgen.

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $1.30.